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Background: α-2,6-sialyltransferase catalyzes the terminal step of complex N-glycan biosynthesis on human
glycoproteins, attaching sialic acid to outermost galactosyl residues on otherwise fully assembled branched glycans.
This “capping” of N-glycans is critical for therapeutic efficacy of pharmaceutical glycoproteins, making the degree of
sialylation an important parameter of glycoprotein quality control. Expression of recombinant glycoproteins in
mammalian cells usually delivers heterogeneous N-glycans, with a minor degree of sialylation. In-vitro chemo-enzymatic
glycoengineering of the N-glycans provides an elegant solution to increase the degree of sialylation for analytical
purposes but also possibly for modification of therapeutic proteins.
Results: Human α-2,6-sialyltransferase (ST6Gal-I) was secretory expressed in P.pastoris KM71H. ST6Gal-I featuring
complete deletion of both the N-terminal cytoplasmic tail and the transmembrane domain, and also partial truncation
of the stem region up to residue 108 were expressed N-terminally fused to a His or FLAG-Tag. FLAG-tagged proteins
proved much more resistant to proteolysis during production than the corresponding His-tagged proteins. Because
volumetric transferase activity measured on small-molecule and native glycoprotein acceptor substrates did not correlate
to ST6Gal-I in the supernatant, enzymes were purified and characterized in their action on non-sialylated protein-linked
and released N-glycans, and the respective N-terminal sequences were determined by automated Edman degradation.
Irrespective of deletion construct used (Δ27, Δ48, Δ62, Δ89), isolated proteins showed N-terminal processing to a
highly similar degree, with prominent truncations at residue 108 - 114, whereby only Δ108ST6Gal-I retained activity.
FLAG-tagged Δ108ST6Gal-I was therefore produced and obtained with a yield of 4.5 mg protein/L medium.
The protein was isolated and shown by MS to be intact. Purified enzyme exhibited useful activity (0.18 U/mg)
for sialylation of different substrates.
Conclusions: Functional expression of human ST6Gal-I as secretory protein in P.pastoris necessitates that N-terminal
truncations promoted by host-inherent proteases be tightly controlled. N-terminal FLAG-Tag contributes extra stability
to the N-terminal region as compared to N-terminal His-Tag. Proteolytic degradation proceeds up to residues
108 – 114 and of the resulting short-form variants, only Δ108ST6Gal-I seems to be active. FLAG-Δ108ST6Gal-I
transfers sialic acids to monoclonal antibody substrate with sufficient yields, and because it is stably produced in
P.pastoris, it is identified here as an interesting glycoengineering catalyst.
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Therapeutic glycoproteins have gained enormous import-
ance in the treatment of serious diseases [1-4]. Clinically
used glycoproteins became one of the fastest growing
markets in the pharmaceutical industry, accounting for 77
high-value drugs out of 642 pharmaceuticals approved
by the European Medicines Agency [4]. One of the
most critical quality attributes of these drugs is the N-
linked glycosylation which is known to have a dramatic
impact on the therapeutic efficacy, serum half-life and
immunogenicity [5,6].
Glycosylation is the most complex and widespread post-
translational modification of proteins [7]. The sophisti-
cated glycosylation machinery needed for the biosynthesis
of therapeutically acceptable glycoprofiles is most likely
provided in mammalian cells [8]. Hence, recombinant
therapeutic glycoproteins are mainly produced in Chinese
hamster ovary (CHO) cell lines but also in cell lines from
baby hamster kidney (BHK-21) and murine tissues [9].
The N-glycans of proteins produced in these cells
closely resemble the human glycan structure but still
differ in crucial points [10-12]. In humans, the terminal
monosaccharides of N-glycans are partially capped with
the sialic acid derivative N-acetylneuramic acid (Neu5Ac)
which strongly affects the solubility, stability and im-
munogenic properties of the respective glycoproteins.
Glycoproteins expressed in CHO cells are also incom-
pletely capped at the terminal monosaccharides [13].
To overcome these problems, the in-vitro glycosylation of
therapeutic proteins by glycosyltransferases (GTs, EC 2.4.)
has attracted the interest of the pharmaceutical industry
since it offers the opportunity to control the glycosylation
of therapeutic proteins to a desired, homogenous and
bioactive glycoform [14,15]. In-vitro sialylation offers the
possibility to complete sialylation of therapeutic glycopro-
teins for analytical purposes, e.g. for analyzing the effect
of sialylation on receptor binding, but also to modify
the drug substance itself. Human sialyltransferases are
a functional family of at least 20 glycosyltransferases which
are subdivided into ST3Gal-, ST6Gal-, ST6GalNAc- and
ST8Sia- families [16,17], depending on the acceptor they
act on (Gal: galactose, GalNAc: N-acetylgalactosamine,
Sia: sialic acid) and the linkage they form (α2,3-, α2,6-,
α2,8-linkage). The ST6 family includes two subfamilies,
ST6Gal-I and ST6Gal-II, both mediating the transfer of
sialic acid in α2,6-linkeage from the donor substrate
CMP-sialic acid to the terminal galactose but with
slight differences in their acceptor specificities [18].
Human ST6Gal-I (β-galactoside α-2,6-sialyltransferase
1, E.C 2.4.99.1) belongs to the CAZy family GT29. Like
all mammalian Golgi-resident GTs, ST6Gal-I features a
type II transmembrane architecture consisting of an N-
cytoplasmic tail, a single transmembrane domain and a
large C-terminal catalytic domain facing the luminalside of the Golgi apparatus [19]. The catalytic domain of
human ST6Gal-I adopts the predicted global GT-A fold, a
seven-stranded central sheet flanked by α-helices, and is
stabilized by three disulfide bindings [20]. The domain
contains two NxS/T motifs for potential N-glycosylation
which is supposed to contribute to the protein stabilization
but is not absolutely required for in-vivo activity [21].
Much effort has already been expended to express
human ST6Gal-I as full-length glycoprotein but without
achieving acceptable activities. For instance, ST6Gal-I
activity in stably transfected CHO cells was restricted to
a crude membrane fraction [22]. ST6Gal-I expressed in
Saccharomyces cerevisiae was retained in the endoplas-
matic rediculum [23] and secretory expression in Pichia
pastoris resulted in only 10 mU/L culture supernatant [24].
Obviously, the strong hydrophobic character of the trans-
membrane domain has clearly restrained the translocation,
folding and solubility of the enzyme. Consequently, human
ST6Gal-I was N-terminally truncated by the hydrophobic
structural domains. As a result, an N-terminally truncated
ST6Gal was now secretory expressed in P.pastoris [25],
and transiently expression of truncated ST6Gal-I in
HEK293 cells resulted in a considerably improved pro-
duction rate [20]. In COS cells, truncated ST6Gal-I was
secreted with a rate of 10 ng of FLAG-ST6Gal-I/106
cells/h [26]. Expression experiments of ST6Gal-I in
CHO cells has shown, that N-terminal truncation of the
first 89 amino acids - including the short N-terminal cyto-
plasmic tail, the transmembrane domain and the stem
region - was tolerated even though the acceptor prefer-
ence got lost, whereas further truncation to residue 100
completely abolished enzymatic activity [27]. The results
led to the conclusion that the conserved motif QVWxKDS
(aa 94–100 in human ST6Gal-I), which has been found
within all sialyltransferase subfamilies, is crucial for activity.
In this work we report on the identification of a mini-
mized catalytic domain of human β-galactoside α-2,6-
sialyltransferase 1 corresponding to Δ108ST6Gal-I and its
soluble expression in P.pastoris for the use in in-vitro
sialylation of therapeutic proteins. Expression of N-
terminally truncated ST6Gal-I variants revealed that the
enzyme is proteolytically degraded in P.pastoris KM71H.
Precise analysis of the degradation products by MS un-
veiled Δ108ST6Gal-I as the main degradation product.
Contrary to the expectations from literature, Δ108ST6Gal-I
was found to be active and catalyzed the transfer of sialic
acid to a humanized monoclonal antibody IgG1. Variant
Δ108ST6Gal-I was successfully expressed in the methylo-
tropic yeast P.pastoris in sufficient yields for a potential
large scale application.
Results and discussion
The production of mammalian proteins like sialyltrans-
ferases put high requirements on expression systems
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form post-translational modifications in order to produce
properly folded and active proteins. Hence, eukaryotic
expression systems like CHO and BHK cells have been
preferably applied for the production of mammalian
proteins. However, the production of proteins in mam-
malian cells is limited due to low expression levels and
high production costs. The methylotrophic yeast Pichia
pastoris offers an alternative expression system since it
combines the unique advantages of prokaryotic growth
characteristics and high expression levels with the ability
to perform posttranslational protein modifications like
glycosylation available only in eukaryotic systems [29]. For
this reason, P.pastoris has been chosen in this work for
the functional expression of human ST6Gal-I.
Protein design for soluble expression of ST6Gal-I
For soluble expression of human ST6Gal-I in P.pastoris,
the N-terminal hydrophobic topology domains were pro-
gressively deleted due to the truncation sites which have
been determined from sequence comparison and published
truncation experiments [26,27].
According to the literature, the cytoplasmic-, transmem-
brane- and stem- (CTS) region contributes to the Golgi
retention [30]. Analysis of the CTS region by the SACS
HMMTOP Algorithm [31] predicts amino acids 1–9 as
the NH2-terminal cytoplasmic tail (CT) followed by a
single transmembrane domain (TMD) ranging from aa
10–27 (Figure 1). The stem region which tethers the
catalytic domain is highly variable in length among the
human STs and assumed to range from aa 28–60 in
human ST6Gal-I. Consequently, the catalytic domain
includes amino acids 61–466. Similar boundaries were
obtained from isolation of a soluble ST6Gal-I from rat
liver tissues lacking a 62 aa NH2-terminal peptide
which indicates aa 63–466 as the catalytic domain [32].Figure 1 Structural domains of human ST6Gal-I (data base entry P159
(aa 10–27). Underlined: stem-region (aa 28–62). Bold and Italics: potential N-glycoAltogether, four different variants were constructed by
progressive truncation of the structural domains i.e. the
short NH2-terminal cytoplasmic tail and the transmem-
brane domain (Δ27ST6Gal-I), the stem region (partially
and fully, yielding Δ48ST6Gal-I and Δ62ST6Gal-I) and
parts of the catalytic domain (Δ89ST6Gal-I). The deletions
were located in the hypervariable region outside the con-
served domain of human ST6Gal-I [23]. The genes coding
for the truncated variants were optimized for expression
in P.pastoris and fused to an N-terminal 6xHisTag.
Production in P.pastoris KM71H
The N-terminally truncated ST6Gal-I variants were pro-
duced in P.pastoris KM71H as secretory protein. In
order to monitor and analyze the expression levels of
the ST6Gal-I variants, samples were withdrawn from the
cultures at the start of induction (0 h) and 24, 48, 72
and 96 h after addition of MeOH. From each culture, al-
iquots of fermentation supernatant were precipitated
with TCA and analyzed by Western Blot (WB) using two
HRP conjugated antibodies for immunodetection, the
polyclonal anti-α2,6ST6 and the monoclonal anti-polyHis.
The antibodies were selected since they recognized differ-
ent sequence parts of the protein and enabled the detec-
tion of the N-terminus (monoclonal anti-polyHis) as well
as the C-terminal sequence (anti-α2,6ST6) of the enzyme.
Comparison of samples drawn after 96 h of induction
revealed conspicuous protein signals (Figure 2, −PI). In
general, strong signals were obtained from detection
with anti-α2,6ST6 which indicated that the expression,
procession and secretion of ST6Gal-I worked sufficiently
in the selected transformants. However, the main protein
bands of the variants occurred just below 40 kDa which
was lower than the expected molecular weights for the
glycosylated enzymes and even lower than the calcu-
lated masses for the deglycosylated forms of Δ27ST6Gal-I07). Italics: cytosolic domain (aa 1–9). Bold: transmembrane domain
sylation sites. N-termini of truncated variants are indicated by a grey arrow.
-PI     +PI         -PI    +PI        -PI   +PI       -PI     +PI







Figure 2 Expression of N-terminally truncated ST6Gal-I variants in P.pastoris KM71H in the absence (−PI) and presence (+PI) of
protease inhibitors. His-tagged enzyme variants were expressed for 96 h with (+PI) and without (−PI) protease inhibitor. WB analysis of
fermentation supernatants (each 600 μL, precipitated with 20% TCA). Immunodetection with HRP conjugated anti-α2,6ST6.
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(40.7 kDa) and Δ89ST6Gal-I (37.9 kDa). Additional
protein bands which were observed at very low molecular
weights strengthened the presumption that proteolytic
degradation has taken place. Moreover, no signals appeared
with anti-polyHis (data not shown) which led to the
conclusion that the proteolytic degradation proceeded
from the N-terminus of each enzyme variant. Generally,
the degradation was also detected at shorter induction
times (data not shown) and increased with proceeding
time. In case of Δ48ST6Gal-I, no degradation products
below 40 kDa were detected after 96 h of induction in
the presence of protease inhibitor but signals occurred
with increasing induction times (data not shown). In
order to reduce proteolysis, the expression of variants
was repeated with addition of protease inhibitors
(Figure 2, +PI). Now, less degradation products were
detected with anti-α2,6ST6 but like before, the main
protein bands appeared around 40 kDa and no signals
were observed with anti-polyHis. Apparently, the addition
of protease inhibitors significantly reduced the degrad-
ation to smaller products below 20 kDa but could not
prevent the first steps of proteolysis concerning the N-
terminus of ST6Gal-I including the His-Tag.
After WB analysis, the fermentation supernatants of
N-terminal truncated ST6Gal-I variants, expressed in the
presence of protease inhibitors, were analyzed regarding
their sialyltransferase activity by measuring the trans-
fer of fluorescence-labeled sialic acid from CMP-9-
fluoresceinyl-Neu5Ac (CMP-9F-Neu5Ac) to asialofetuin
[33]. Measurements at 37°C and pH 6.5 resulted in
34 mU/L for Δ27ST6Gal-I, 80 mU/L for Δ48ST6Gal-I
and 115 mU/L for Δ62ST6Gal-I and Δ89ST6Gal-I,respectively. Interestingly, the activities did not correlate
with the expression levels of the main protein bands in
Figure 2 (+PI) which might indicate that most of the
immuno-detected enzyme variants were degraded to less
active or inactive products and only small amounts of
active protein were existent. In general, the volumetric
enzyme activities increased with progressive truncation
of ST6Gal-I.
Functional characterization of ST6Gal-I variants and
identification of Δ108ST6Gal-I
Expression analysis of differently truncated ST6Gal-I vari-
ants clearly demonstrated that the enzyme was degraded
to specific cleavage products accompanied by a loss of
activity. For identification of the main cleavage site and
its impact on activity, the dominating protein band at
approximately 40 kDa of each ST6Gal-I variant (except
of the lowest active Δ27ST6Gal-I) was purified from the
fermentation supernatant (Additional file 1: Figure S1)
and subjected to an extensive characterization. First, the
specific activity for the sialic acid transfer from CMP-9F-
Neu5Ac to asialofetuin was measured and calculated as
RFU/μg. Afterwards, ST6Gal-I was tested regarding
sialylation activity using the Fc glycan of a highly galacto-
sylated humanized monoclonal antibody IgG1 as acceptor
substrate (Additional file 2: Figure S2). This assay allowed
the determination of the sialylation degree, i.e. if one or
two sialic acids are attached to the glycan structure. At
the start of the sialylation procedure the IgG1 holds no
sialic acid residues, just two galactose units (denoted as
G2). During incubation with ST6Gal-I, one sialic acid
(G2 + 1SA) or even two sialic acids (G2 + 2SA) can get
attached to the G2 structure. Determination of G2 + 1SA
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ionization mass spectrometry of the transfer reaction
samples. In a last step, the N-terminal sequence of a
purified sample of each variant was determined by
Edman degradation. After deglycosylation, the amino
acid sequences of the different ST6Gal-I variants were
deduced from MS analysis. From each variant, several
batches were characterized. The most significant results
are summarized in Table 1.
Interestingly, activity of purified Δ48ST6Gal-I towards
asialofetuin was not detectable but the variant formed
7% G2 + 1SA when assayed towards IgG1. Variant Δ62
ST6Gal-I showed a low batch-to-batch reproducibility
which was reflected by fluctuating transfer activities
(Table 1). Specific activities ranging from 70 to 689
RFU/μg were obtained for asialofetuin and a similar
performance was observed towards IgG1. While batches
with lower activities on asialofetuin (70 to 208 RFU/μg)
also displayed low capability to sialylate the terminal
galactosyl moieties of IgG1 (22 to 29%), batches of
Δ62ST6Gal-I which were highly active on asialofetuin
(664 and 689 RFU/μg) were able to mask much more of
total galactosyl moieties available. Formation of G2 + 1SA
was favored (63–82%), however, disialylation (G2 + 2SA)
was also observed at a reasonable extent of 15 – 34%
(based on initial G2 + 0SA concentration). After purifi-
cation, variant Δ89ST6Gal-I showed no transfer activity
towards asialofetuin or IgG1 anymore. Hence Δ89ST6Gal-I
was not further investigated.
Mass analysis of the different constructs confirmed the
presumption from WB analysis of the fermentation super-
natants with anti-polyHis that in each case the N-terminal
sequence of ST6Gal-I has been fully degraded to products
corresponding to Δ108 – Δ114 truncations. In general,Table 1 Analytic data of N-terminally truncated ST6Gal-I cons
Construct Intensity of
variant in ESMS [%]
MS analysis Trun
Δ48ST6Gal-I 100 NYLS… Δ114
Δ62ST6Gal-I* 75 NYLS… Δ114
25 WKNYLS… Δ112
Δ62ST6Gal-I 30 LQKIWKNYLS… Δ108
70 NYLS… Δ114




Δ62ST6Gal-I 100 LQKIWKNYLS… Δ108
Δ62ST6Gal-I 100 LQKIWKNYLS… Δ108
Δ89ST6Gal-I - - -
n.d. not detectable.
*Due to the low reproducibility, several batches of variant Δ62ST6Gal-I have been athe transfer activities correlated well with the N-terminal
truncations. The low active Δ48ST6Gal-I was found to be
solely present as Δ114 product starting with NH2-NYLS.
Batches of Δ62ST6Gal-I performing best on asialofetuin
and IgG1 were strictly existent as Δ108 variants starting
with NH2-LQKIWKNYLS whereas batches with lower
activities on acceptor proteins contained mixtures of
truncated products ranging from Δ111 (NH2- IWKNYLS)
to Δ114 (NH2-NYLS). Apparently, the presence of the
Δ108ST6Gal-I construct correlated well with the observed
transfer activities. Interestingly, Δ108ST6Gal-I was still
very active even though significant parts of the predicted
catalytic domain were missing. This is contradicting to
previous studies [26,27] reporting that the conserved se-
quence QVWxKDS covering residues 94–100 is crucial
for activity. Proceeding degradation from Δ108 to Δ114
drastically reduced and almost abolished enzyme activity
as demonstrated for Δ48ST6Gal-I which ended up in
100% of Δ114. Since only low amounts of Δ111 and Δ112
were found we assumed that the degradation from Δ108
to Δ114 proceeds very fast. The results strongly support
that not only the stem region but also N-terminal se-
quence parts of the predicted catalytic domain are highly
sensitive to proteolytic processing events like they occur
also in nature. Glycosyltransferases are type II membrane
proteins and often retained in the Golgi apparatus.
However, some of the enzymes are cleaved by endogen-
ous proteases and secreted out of the cell [34]. These
proteolytic cleavage events frequently occur in the stem
region and release a catalytically active fragment of the
glycosyltransferases [34]. Hence, glycosyltransferases have
been initially isolated from various body fluids [35]. Sol-
uble ST6Gal-I has been purified first from goat, bovine,
and human colostrum [36] and from rat liver missing 63tructs
cation IgG1 Asialofetuin
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has been demonstrated that the β-amyloid-converting
enzyme 1 (BACE1) is responsible for cleavage and secre-
tion of human ST6Gal-I into the plasma [37]. BACE1 is a
membrane-bound aspartic acid protease that cleaves the
amyloid precursor protein to produce the neurotoxic
amyloid β-peptide, which is a crucial initiation process of
the pathogenesis of Alzheimer’s disease. Investigation
of this proteolysis by incubation of rat ST6Gal-I (88%
similarity to human ST6Gal-I) with BACE1 revealed that
the enzyme was first cleaved between Leu37 and Gln38 to
generate the sequence Gln38-Ala39-Lys40-Glu41-Phe42 at
the N-terminus. In a second step, peptide Gln38-Ala39-
Lys40 was trimmed by luminal aminopeptidase(s) yielding
Glu41 as the N-terminal amino acid of the soluble
ST6Gal-I. It is assumed that the generation of soluble
ST6Gal-I by BACE1 is needed for the sialylation of
soluble plasma glycoproteins to protect them from
clearance by the hepatic asialoglycoprotein receptors
[37]. This two-step process of proteolytic degradation
bears certain resemblance to the degradation of human
ST6Gal-I during expression in yeast concerning the way it
proceeds. The cleavage started between Arg108 and Leu109
and proceeded to Asn115 in Leu109-Gln110-Lys111-Ile112-
Trp113-Lys114-Asn115-Tyr116. In both cases the final cleavage
takes place after a Lysine residue. The proteolytic sensitivity
of the stem region is highly relevant for physiological
processes but strongly affects the stability during expres-
sion in yeast.
Expression and characterization of FLAG-Δ108ST6Gal-I
In order to confirm the activity of the newly identified
Δ108ST6Gal-I variant and to evaluate its potential for
large scale application, the variant was cloned into
pPICZαB and expressed in P.pastoris KM71H without
addition of protease inhibitor. In a first approach, vari-
ant Δ108ST6Gal-I was expressed without Tag as well as
N-terminally fused to the 6xHisTag (Additional file 3:
Figure S3). In both cases, strong degradation was detected
by Western Blot analysis yielding inactive degradation
products as determined by the activity assay. SDS-PAGE
analysis of untagged ST6Gal-I revealed high amounts of
enzyme at 40 kDa whereas the His-tagged ST6Gal-I was
much lower expressed. The results gave reason to suspect
that the highly charged HisTag might additionally increase
proteolysis. For this reason, the hydrophilic FLAG-Tag
peptide was N-terminally fused to the protein for protec-
tion against proteolysis yielding FLAG-Δ108ST6Gal-I.
SDS-PAGE analysis of culture supernatants drawn at
certain time points after induction (Figure 3A) revealed
that FLAG-Δ108ST6Gal-I was produced and secreted in
unexpected high amounts and purity without overloading
the secretory pathway of P.pastoris. At all time points,
two protein bands, running closely together at about40 kDa, appeared at the SDS-PAGE. Immunodetection
with anti-α2,6ST6 generated two signals (Figure 3B).
After stripping, the membrane was re-used for detection
with anti-FLAG which recognized solely the upper protein
band (Figure 3C). The results indicated that variant
FLAG-Δ108ST6Gal-I was not only present as the entire
protein but also as an N-terminally truncated variant
lacking the FLAG-Tag and presumably a few amino acids
of the catalytic domain. The weaker signals obtained with
anti-FLAG might probably be caused by the re-usage of
the membrane after stripping and do not reflect original
protein concentrations. In contrast to the Δ27-Δ89ST6Gal-
I variants, no further proteolysis to smaller degradation
products did occur, which provides evidence for an im-
proved stability of FLAG-Δ108ST6Gal-I. Due to the highly
similar surface charges the two protein bands could not be
completely separated by ion exchange chromatography.
Hence, a FLAG-Δ108ST6Gal-I variant comprising a certain
percentage of truncated and therefore less active or inactive
protein was used for further characterization.
So far, only little information has been published on
specific activities of ST6Gal-I. This might be attributed
to the poor availability of the enzyme. ST6Gal-I isolated
from human liver revealed a transfer activity of 1.2 U/mg
using CMP-9F-Neu5Ac and asialofetuin as donor and
acceptor substrate, respectively [33]. Specific activities of
6 · 10−5 U/mg [23] and 3 · 10−4 U/mg [38] were obtained
for the sialyltransfer from CMP-[14C]-Neu5Ac towards
asialofetuin for the human full-length ST6Gal-I expressed
in Saccharomyces cerevisiae before and after up-scale
(150-L bioreactor). Expression of a human ST6Gal-I con-
struct, lacking the transmembrane domain, in insect cells
yielded an enzyme preparation with 1.6 U/mg towards
asialofetuin when assayed with the radio-labeled sugar
donor [39]. In this work, the specific activity of FLAG-
Δ108ST6Gal-I was not only determined towards high- but
also towards low-molecular weight acceptors (Table 2).
Using an HPLC-based assay, specific activities of 0.05 and
0.18 U/mg were obtained for asialofetuin and lactosamine,
respectively. These values are intermediate to the specific
activities reported above. However, comparison with data
from literature has to be treated with caution, due to the
different assay conditions used and the great variation in
enzyme length and glycosylation pattern. But not only
transferase activity is an important parameter for enzyme
usability in biocatalysis. In general, the main obstacle for
application of glycosyltransferases is the presence of differ-
ent hydrolytic side reactions [40]. Therefore, we also had a
look on sialidase activity and donor sugar hydrolysis.
While α2,6-sialidase activity was not observed within the
detection limit of 10−5 · U/mg, CMP-Neu5Ac was hydro-
lyzed with a specific activity of 0.03 U/mg (Table 2). This
hydrolase activity of human Δ108ST6Gal-I is substantial,
however, it is still 100-fold lower compared to bacterial
Figure 3 Expression analysis of human FLAG-Δ108ST6Gal-I in P.pastoris. Analysis by A) SDS-PAGE and Western Blot using B) anti-α2,6ST6
and C) anti-FLAG for detection. Lane 1: Novex sharp protein standard; lane 2–6: fermentation supernatant (300 μL TCA precipitated) after 24, 48,
72, 96 and 120 h of induction in shake flasks without addition of protease inhibitor.
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nucleotides could partially compensate for the loss in
efficiency of bacterial counterparts [43,44]. Few rele-
vant protein engineering strategies are reported which
rely on a more detailed understanding of the underlying
molecular mechanism [41]. However this is beyond the
scope of this work.
Expression of a minimized catalytic Δ108 domain in
the presence of an N-terminal FLAG-Tag could remark-
ably improve the stability of ST6Gal-I during enzyme
production (Figure 3). Nevertheless, proteolytic degradation
did still occur to a certain degree during expression in
shake flasks. It is known that temperature, pH and medium
composition strongly influence the proteolytic activity of P.
pastoris [45]. Hence, FLAG-Δ108ST6Gal-I was produced
in a 5-L fed-batch bioreactor which offered the opportunity
to tightly control the process conditions for potential
reduction of proteolysis during the long expression
phase. Expression of FLAG-Δ108ST6Gal-I was performed
at 20°C and pH 5.2 for 48 h. The culture supernatant wasTable 2 Multifunctionality of human FLAG-Δ108ST6Gal-I
Enzyme activity Donor Acceptor Specific activity
[U/mg]
α2,6-Sialyltransferase CMP-Neu5Ac Lactosamine 0.18 ± 0.01
CMP-Neu5Ac Asialofetuin 0.05 ± 0.01
CMP-Neu5Ac hydrolase CMP-Neu5Ac - 0.03 ± 0.01
α2,6-Sialidase 6′-Sialyllactosamine - n.d.
n.d., not detectable.purified via anion exchange chromatography. Typically,
4.5 mg of purified protein were obtained from 1 L fermen-
tation supernatant.
Analysis of the N-terminus by Edman degradation
(Table 3) confirmed that 85% of the deglycosylated enzyme
was present as the entire protein and only low amounts of
enzyme were degraded to Δ114 (10%) and Δ115 (5%). In
comparison, only 50% of Δ108 but also 50% of Δ114 was
detected in shake-flask experiments (data not listed).
However, the specific activity (33 RFU/μg) was not signifi-
cantly increased compared to a value of 20 RFU/μg
obtained from shake-flask expression. Summing up, no
substantial reduction in proteolysis during expression
could be achieved under the fed-batch conditions used.
Moreover, FLAG-Δ108ST6Gal-I did only form 14% of
the G2 + 1SA N-glycan when assayed towards IgG1 and
no G2 + 2SA N-glycan product was obtained at all. This
is an interesting finding because variant Δ62ST6Gal-I,
which was fully degraded to Δ108 (Table 1), showed
60–80% G2 + 1SA and 15–30% G2 + 2SA formation.
However, it cannot be concluded if the reduced activity
is caused by the truncation of the enzyme or the FLAG
Tag. A study on acceptor substrate specificity revealed
a correlation between the enzyme length and activity
[26]. The transfer efficiency was decreased up to 6-fold
for truncated enzymatic forms (Δ28-Δ80) carrying an
N-terminal Flag-Tag compared to the full-length enzyme.
Legaigneur and co-workers [26] postulated that parts of
the stem-region might participate in formation of the
acceptor binding pocket. A recent crystal structure of
human ST6Gal-1 reveals the possible binding mode of
Table 3 Analytic data of human FLAG-Δ108ST6Gal-I expressed under fed-batch conditions
Construct Intensity of variant
in ESMS [%]
MS analysis Truncation IgG1 Asialofetuin
G2 + 1SA [%] G2 + 2SA [%] Fetuin [RFU/μg]
FLAG-Δ108ST6Gal-I* 85 DYKDDDDKLQKIWKN… Δ108 14 0 33
10 NYLS… Δ114
5 YLS… Δ115
*The FLAG-Δ108ST6Gal-I construct was obtained from a 5-L fermentation.
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of residues 108–122 with the glycan acceptor.
It is also relevant to consider results of Malissard et al.
[25] who have studied the expression of human ST6Gal-
I in P. pastoris previously. The authors reported on the
expression of a soluble ST6Gal-I with 3 U/L maximal
activity in the culture supernatant. The current study
extends the earlier work in presenting specific activities
of purified enzymes on lactosamine as well as on non-
sialylated protein-linked and released N-glycans. Enzyme
activities are generally difficult to compare, but reported
3U/L exceed herein found 720 mU/L by 4-fold. How-
ever, one has to consider that the calculation of the
data in this study is based on analysis of the purified
protein without taking into consideration the potential
loss of protein and activity caused by the downstream
processing. Additionally, Malissard et al. measured the
transfer reaction of CMP to LacNAc using a radiolabed
sugar whereas in this study the transfer reaction rate
was determined by the unlabeled and therefore less
sensitive CMP-NANA. Beside the specific activities of
purified enzymes, we show that N-terminal truncations
are highly important for protein stability and activity
and prove for the first time activity of a Δ108ST6Gal-I
construct, while a deletion of 100 aa led to complete
inactivation of human ST6Gal-I when transiently expressed
in CHO cells [26].Conclusions
Precise analysis of degradation products, which were
obtained during expression of N-terminally truncated
human ST6Gal-I variants in P.pastoris KM71H, led to the
identification of a minimal catalytic domain corresponding
to Δ108ST6Gal-I. So far, it has been reported in literature
that the deletion of more than 100 amino acids completely
abolished enzyme activities. In this work we have demon-
strated that N-terminal truncation of 108 amino acids
maintained the activity. Additionally, expression of the
N-terminal Flag-tagged Δ108ST6Gal-I clearly indicated
an improved stability of the enzyme against proteolysis.
FLAG-Δ108ST6Gal-I catalyzed the transfer of sialic
acid to the galactosyl residues of a humanized antibody
which verified the potential for in-vitro glycosylation of
therapeutic proteins.Materials and methods
Chemicals, Strains and Vectors
E. coli XL-1 Blue, P.pastoris KM71H and vector pPICZαB
were purchased from Invitrogen (Austria). Asialofetuin,
CMP-Neu5Ac, CMP-9F-Neu5Ac and cOmplete protease
inhibitor tablets were obtained from Roche (Germany).
Anti-α2,6-Sialytransferase© Rabbit IgG Antibody solution
was purchased from IBL (Japan, #1898), monoclonal anti-
polyHis from Sigma-Aldrich (Germany).General recombinant DNA techniques
Phusion DNA Polymerase (Finnzyme) and dNTP’s from
MBI Fermentas (Germany) were used for PCR. The PCR
was performed in a Gene Amp® PCR 2200 thermocycler
(Applied Biosystems, USA). Digestion of DNA was
performed with restriction endonucleases from New
England Biolabs (USA). Wizard® Plus SV Minipreps
DNA Purification System (Promega, Germany) was
utilized to prepare plasmid DNA. PCR products and
DNA fragments were purified by the Wizard® SV Gel
and PCR Clean-up System (Promega, Germany).Construction and transformation of the recombinant plasmids
The gene coding for the human ST6Gal-I lacking the
transmembran anchor (Δ27ST6) was codon optimized for
P.pastoris and synthesized by the GeneArt® Gene Synthe-
sis Service (Life Technologies, Germany). The synthesized
DNA fragment was digested with XhoI and NotI and
cloned into pPICZαB behind the α-factor yielding pPIC-
ZαB_Δ27ST6 (Figure 4).
The DNA fragment included the XhoI restriction site, the
P.pastoris Kex2 protease cleavage site, an ALE-6xHisTag
coding peptide, the NdeI restriction site, the optimized
gene, the stop codon and the NotI restriction site. The
respective truncated versions Δ27ST6Gal-I, Δ48ST6Gal-I,
Δ62ST6Gal-I, Δ89ST6Gal-I and Δ108ST6Gal-I of the gene
encoding human ST6Gal-I were amplified by PCR from
pPICZαB_Δ27ST6 using the primers listed in Additional
file 4: Table S1. The following conditions were employed
for PCR amplification (30 cycles): 98°C for 30 s, 98°C for
10 s, 62°C for 25 s, 72°C for 40 s and 72°C for 7 min with
Phusion® DNA polymerase. The PCR mixtures were
purified, digested with NdeI/NotI, ligated into pPIC-
ZαB_Δ27ST6 restricted with NdeI/NotI and transformed
Figure 4 Schematic representation of the pPICZαB-based P.pastoris expression vectors employed in this study. pAOX1: alcohol oxidase 1
gene promoter; α-factor: coding region for the signal sequence of S. cerevisae α-mating factor; 6xHis: coding sequence for 6 histidines; Flag: coding
sequence for the Flag-Tag; Kex2: coding sequence for Kex2 protease cleavage sites; human ST6Gal-I: coding sequence for the truncated variants of
human ST6Gal-I.
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confirmed by DNA sequencing.
Introduction of the N-terminal FLAG-Tag (Figure 4)
was performed by PCR using plasmid pPICZαB_Δ108ST6
as template and the primer pair 5′-TATCTCTCGA
GAAAA-GAGATTACAAGGATGACGACGATAAGTT
GCAGAAGATTTGGAAGAACTACTTGC-CATGAAC
AAG-3′ for amplification. The reaction was performed
with Phusion® DNA polymerase accordingly to the manu-
facturer’s instructions.
Transformation and selection for multi-integration events
About 1 μg of each plasmid was linearized with SacI and
transformed into 80 μL of freshly prepared competent
cells of KM71H by electroporation at 1500 V, 25 μF and
600 Ω using a Gene Pulser (BioRad). Transformed cells
were plated out on agar plates supplemented with
100 μg/mL Zeocin and incubated at 30°C. Transformants
were cultivated in microtiter plates and screened for
multiple plasmid integration events on agar plates using
Zeocin concentrations from 100 – 2,000 μg/mL. Selected
clones were stored in MTP at −80°C.
Expression of ST6Gal-I
Expression in Deep Well plates
Transformants were cultivated in deepwell plates (96-well
format) in a Multitron II stackable incubation system
(Infors, Bottmingen, Switzerland). Briefly, following a 12 h
long incubation in 600 μL BYPD medium (1% yeast
extract, 2% peptone, 2% glucose, 200 mM potassium
phosphate buffer pH 7) at 320 rpm, 28°C and 80% air
humidity, cells were induced by addition of BBM (1%
glycerol, 1.34% yeast nitrogen base, 4×10−5% biotin, 1%
(v/v) methanol, 200 mM potassium phosphate buffer
pH 7). Following induction cycle was performed: 12 h
0.5% MeOH – 12 h 1% MeOH – 12 h 0.5% MeOH – 12 h
1% MeOH. After 48 h of induction, cells were harvested
by centrifugation (4°C, 2000 rpm, and 20 min). Culture
supernatants and cell pellets were used for analysis of
activity and expression levels.Expression in shake flasks
Transformants were used to inoculate a 1-L baffled
shake flask containing 200 mL BMGY broth (1% yeast
extract, 2% peptone, 1% glycerol, 4×10−5% biotin, 100 mM
potassium phosphat buffer pH 6). The cultures were incu-
bated at 28°C, 250 rpm for approximately 16–18 h until an
OD600 of 2–6 was reached. The cells were harvested by
centrifugation at 3,000 × g for 5 min and the cell pellet was
resuspended in 1/10 of the original volume (20 mL). The
culture was placed in a 100-mL baffled shake flask. Expres-
sion was induced by the addition of methanol to a final
concentration of 0.5%. Samples were collected after 48, 72,
96 and 120 h of induction in the presence (+PI) or absence
(−PI) protease inhibitor and stored at −20°C.
5-L Fermentation
A similar work-up procedure, as described above, was used.
In a first step, two liters of supernatant were centrifuged
(15 min at 8,500 rpm), filtrated (0.2 μm), concentrated (to
150 mL, Pellicon 2 Mini Ultrafiltration Module, 10 kDa
membrane, 0,1 m2 (Millipore)) and dialyzed against 20 mM
potassium phosphate, pH 6.5 (buffer A) and concentrated.
The dialysate was loaded onto an S-Sepharose FF column
(5.0 × 5.1 cm), equilibrated with buffer A. After washing
with 600 mL buffer A, the enzyme was eluted with a linear
gradient of 0–200 mM NaCl within 200 mL. A second
wash step with 200 mM NaCl (300 mL) was performed.
Fractions (50 mL) were analyzed by SDS-PAGE.
Purification of ST6Gal-I
From shake flasks
A two-step work-up procedure was used. In a first step,
the culture supernatant was centrifuged (10 min at
3,000 rpm), filtrated (0.2 μm) and dialyzed against 20 mM
potassium phosphate, pH 7.0. The dialysate was loaded
onto a HisTrap HP FF 5-mL column (GE Healthcare,
Germany) at a flow rate of 2 mL/min. After a washing step
of 10 column volumes, the enzyme was eluted with a
linear gradient of 0–500 mM imidazol within 10 column
volumes. Fractions of 2-mL were collected and analyzed
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pooled and buffer was exchanged to 50 mM MES, pH 6.5.
From 5-L fermentation
A similar work-up procedure, as described above, was used.
In a first step, two liters of supernatant were centrifuged
(15 min at 8,500 rpm), filtrated (0.2 μm), concentrated
(to 150 mL, Pellicon 2 Mini Ultrafiltration Module,
10 kDa membrane, 0,1 m2 (Millipore)) and dialyzed
against 20 mM potassium phosphate, pH 6.5 (buffer A)
and concentrated. The dialysate was loaded onto an S-
Sepharose FF column (5.0 × 5.1 cm), equilibrated with
buffer A. After washing with 600 mL buffer A, the enzyme
was eluted with a linear gradient of 0–200 mM NaCl
within 200 mL. A second wash step with 200 mM NaCl
(300 mL) was performed. Fractions (50 mL) were analyzed
by SDS-PAGE.
SDS-PAGE and Immunoblotting
Analytical SDS gel electrophoresis was carried out using
NuPAGE gels (4–12%, Invitrogen). Samples (36 μL) were
diluted with 12 μL NuPAGE LDS sample buffer (Invitro-
gen) and incubated for 2 min at 85°C. Aliquots, typically
containing 5 μg of protein were loaded on the gel. The
gels were stained using SimplyBlue SafeStain (Invitrogen).
For Dot Blot analysis, 5 μL of the culture supernatant
from deepwell cultivation were loaded onto a Biodyne® A
nylon 6.6 membrane (pore size 0.45 μm, Pall Corporation,
Germany) and tried for 1 h at 60°C. For Western Blot ana-
lyses, protein samples were separated by SDS-PAGE and
blotted onto PVDF Transfer membranes (Amersham
Hybond-P, GE Healthcare). Dot Blots and Western Blots
were treated similarly for receptor detection: the mem-
branes were washed twice with 20 mL TBS for 7 min at
room temperature with shaking and blocked for 1 h at
room temperature in TBS buffer (10 mM Tris HCl,
pH 7.5 and 150 mM NaCl) containing 3% (w/v) BSA.
After 2× washing with TBS-Tween/Triton buffer (Qiagen,
20 mM Tris HCl pH 7.5, 500 mM NaCl, 0.05% (v/v)
Tween 20, 0.2% (v/v) Triton X-100) and 1× washing with
TBS buffer (for each time at room temperature, 7 min
with shaking), the membranes were incubated with the
Anti-α2,6-Sialytransferase© Rabbit IgG Antibody solution
(2 μg/mL dilution in blocking buffer of antibody) at room
temperature for 1 h. The membranes were washed twice
with TBS-Tween/Triton buffer and once with TBS buffer
each time for 7 min at room temperature. Then the mem-
brane was incubated with secondary antibody (1/5000),
dilution in blocking buffer of antibody horseradish per-
oxidase (HRP conjugated) for 1 h at room temperature.
The membranes were washed twice for 7 min with TBS-
Tween/Triton buffer at room temperature followed twice
for 7 min with TBS buffer and incubated with 7.5 mL of
SuperSignal West Pico Substrate Working Solution for3 min. Detection was performed using the G:Box F3
(Syngene).
Mass spectrometry
The molecular masses of variants of human ST6Gal-I
expressed in P.pastoris were analyzed by mass spectros-
copy. Therefore, the deglycosylated forms of human
ST6Gal-I were prepared and analyzed using Micromass
Q-Tof Ultima and Synapt G2 HDMS devices (Waters UK)
and the MassLynx V 4.1 software. For deglycosylation,
samples were denatured and reduced; 45 μL denaturing
buffer (6 M guanidine hydrochloride) and 13 μL TCEP
(0.1 mM, diluted in denaturing buffer) were added to
100 μg sialyltransferase. An appropriate volume of ultra-
pure water was added to reach an overall concentration of
about 4 M of guanidine hydrochloride. After incubation of
the sample for 1 h at 37°C the buffer was changed using
a Bio-SpinR 6 Tris column (BioRad), which was pre-
equilibrated with ultrapure water. The whole sample was
applied onto the column and eluted by centrifugation. To
the resulting eluate, 5.5 μL of a 0.1 U/μL solution of
PNGase F was added and the mixture was incubated at
37°C overnight. Afterwards the samples were adjusted to
30% ACN and 1% FA and analyzed by electrospray
ionization mass spectrometry.
N-terminal sequencing by Edman degradation
The N-terminal sequences of expressed variants of human
ST6Gal-I were analyzed by Edman degradation using
reagents and devices obtained from Life Technologies.
Preparation of the samples was done as described in the
instruction manual of the ProSorb Sample Preparation
cartridges and the ProBlott Mini PK/10 membranes.




Enzymatic activity was determined by measuring the
transfer of fluorescence-labeled sialic acid to asialofetuin
according to the literature [20]. Enzymatic activity was
expressed as RFU/μg (relative fluorescence unit). 10,000
RFU/μg correspond to a specific activity of 0.084 U/mg.
HPLC-based assay
The reaction mixture consisted of 0.75 mM CMP-
Neu5Ac, 10 mM lactosamine or 0.35 mM asialofetuin
and 1 μM purified enzyme solution in 20 μL of 50 mM
MES, pH 6.5 containing 0.1% Triton X-100. The enzym-
atic reaction was carried out at 37°C and 300 rpm. All
assays were performed in duplicate. The enzymatic reac-
tion was stopped after a certain time of incubation by
quenching on ice and addition of 40 μL of ice-cold
acetonitrile. The reaction mixture was centrifuged at 4°C,
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After appropriate dilution, 10 μL were injected to HPLC
analysis using a Chromolith® Performance RP-18 (100 ×
4.6 mm; Merck Chemicals, Germany) column in reversed
phase ion-pairing mode on an Agilent Technologies 1200
Series system. The column was equilibrated with 20 mM
phosphate buffer, pH 6.8 containing 2 mM tetrabuty-
lammonium at a flow rate of 2 mL/min. A temperature
control unit maintained 30°C throughout the analysis.
Samples were eluted with a linear gradient from 0–2%
acetonitrile in 3 min followed by 2–25% acetonitrile in
7 min and detected by UV at 254 nm. The increase of
CMP and the decrease of CMP-Neu5Ac were recorded.
One unit (1 U) was defined as the amount of enzyme that
could transfer 1 μmol of sialic acid per min to lactosamine
under the conditions described above.
Hydrolase and Sialidase assay
The reaction mixture for determination of CMP-Neu5Ac
hydrolase activity consisted of 0.75 mM of CMP-Neu5Ac
and 1 μM of purified enzyme in 20 μL of 50 mM MES,
pH 6.5 containing 0.1% Triton X-100. Reactions were
allowed to proceed for 0.5, 10, 15, 30 and 60 min at 37°C
and 300 rpm. The reaction products were analyzed by
HPLC as described above.
The reaction mixture for determination of α2,6-sialid-
ase activity consisted of 1.5 mM of 6′-sialyllactosamine,
0 or 1.0 mM CMP and 1 μM of purified enzyme in
20 μL of 50 mM MES, pH 6.5 containing 0.1% Triton X-
100. Reactions were allowed to proceed for up to 22 h at
37°C and 300 rpm. The reaction products were analyzed
by HPAE chromatography on a Dionex BioLC system
equipped with a CarboPac® PA200 column (3 × 250 mm;
Thermo Fisher Scientific Inc., Dionex) and a CarboPac®
guard column. 25 μL of sample were injected and eluted
using an isocratic concentration of 100 mM NaOH
with 40 mM sodium acetate and a flow rate of 0.5 mL/
min at 30°C. An ED50 electrochemical detector with a
carbohydrate certified gold working electrode was used
for pulsed amperometric detection (PAD) in the carbo-
hydrate waveform (as recommended from the supplier).
Increase of sialic acid and decrease of 6′-sialyllactosamine
was recorded.
Sialylation of monoclonal antibody
A highly galactosylated humanized monoclonal antibody
IgG1 was used in sialylation experiments. The reaction
mixture contained IgG1 (300 μg in 54 μL 35 mM sodium
acetate/Tris buffer pH 7.0), the donor substrate CMP-
Neu5Ac (150 μg in 50 μL water) and sialyltransferase
(30 μg in 26 μL 20 mM potassium phosphate, 0.1 M NaCl,
pH 6.5). The samples were incubated at 37°C for a defined
time. To stop the reaction 100 μL denaturing buffer (6 M
guanidine hydrochloride) and 30 μL TCEP (0.1 mM,diluted in denaturing buffer) were added to the samples
and the samples were incubated at 37°C for 1 h. The sam-
ples were buffered in electrospray-medium (20% ACN, 1%
FA) using pre-equilibrated illustraTM Nap5-Columns
(GE-Healthcare). Samples were analyzed by electrospray
ionization mass spectrometry and the content of G2 +
0SA, G2 + 1SA and G2 + 2SA N-glycans was determined.
A Micromass Q-Tof Ultima and a Synapt G2 HDMS
device (Waters UK) and the MassLynx V 4.1 software
were used.
Additional files
Additional file 1: Figure S1. SDS-PAGE of purified ST6Gal-I expressed
in P.pastoris KM71H with protease inhibitors. Lane 1: Δ62ST6Gal-I; lane 2:
Δ48ST6Gal-I; lane 3: Δ89ST6Gal-I; lane 4: Novex Sharp Protein Standard.
Additional file 2: Figure S2. Sialylation of Fc glycan.
Additional file 3: Figure S3. Expression of Δ108ST6Gal-I without Tag
(A) and with N-terminal HisTag (B) in the presence of protease inhibitor.
Expression analysis by Western Blot/ anti-ST6Gal-I and SDS-PAGE.
Additional file 4: Table S1. Primer sequences for truncation of human
ST6Gal-I.
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